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Basal cell carcinoma (BCC) is the most common human malignancy. Both epidemiological and direct evidence have established
ultraviolet (UV) exposure from the sun as the most important risk factor for BCC development. There has only been one
randomized and controlled study to examine sunscreen’s role in the prevention of BCC, and no signiﬁcant protective beneﬁt
was found. This study did not address four important concepts: sunscreen abuse, sunscreen misuse, sunscreen formulation,
and cumulative UV exposure. Thus, the results of this study are diﬃcult to interpret and extrapolate with real-world sunscreen
practices.
1.Introduction
Basal cell carcinoma (BCC) is the most common cutaneous
malignancy, the most common human malignancy overall,
and its incidence is increasing [1]. For more than 80 years,
convincing epidemiological evidence has linked sun expo-
sure with skin cancer. BCC is more frequent in patients with
higher cumulative sun exposure, with more sun-sensitive
skin types, from areas of high ambient solar irradiance, and
on sun-exposed body sites [1, 2].
Both the quality and quantity of such epidemiological
evidence have improved over those 80 years, and more
recent data have given us direct evidence of ultraviolet-
(UV-) induced mutations in genes important to BCC de-
velopment. UV-induced mutations in the p53 tumor-sup-
pressor gene have been found in more than half of BCC cases
[3]. Mutations that activate the Hedgehog intercellular sig-
naling pathwaygenes, including PTCH, Sonic hedgehog, and
Smoothened, play a signiﬁcant role in the development of
BCC, and these mutations have also been shown to be UV
induced [4].
UVBexposureseemstobethemostimportantriskfactor
in developing BCC [2, 4–7]. Rats exposed to UVB develop
BCCaswell[8].UVAhasalsobeenimplicatedasariskfactor
for BCC, including exposure during the use of tanning beds
[9, 10].
2. Evidence of Sunscreenand BCC
With the propensity of both epidemiologic and direct evi-
dence indicating the chief role of UV in the development
of BCC, one may expect a similar propensity of evidence
indicating that UV blockade by sunscreen protects against
BCC.Todate,therehasonlybeenonerandomizedcontrolled
trial examining sunscreen’s role in the prevention of skin
cancer,anditshowednosigniﬁcantprotectivebeneﬁtofsun-
screen with relation to BCC [11].2 Journal of Skin Cancer
Green et al.’s 1999 study followed 1621 Australian pa-
tients for 4.5 years. There was both a daily SPF 16 sun-screen
group and a no-sunscreen group that included no placebo
lotion. At the end of this trial, 75% of the daily sunscreen
group patients were applying sunscreen to their head, neck,
arms,andhands3or4daysperweek,andthiscorrelatedwell
with the measured weight of sunscreen at scheduled study-
clinic visits. In the no-sunscreen group, 74% of patients were
not using sunscreen at all or no more than 1-2 days per week
[11]. The no-sunscreen group was in fact allowed to wear
sunscreen, and 26% of that group was using sunscreen more
than 2 days per week.
Skin cancer diagnoses were obtained by scheduled study-
clinic visits 2 and 4 years after the initiation of the study,
utilizing blinded dermatologists to make clinical diagnoses,
which were also conﬁrmed histologically. Diagnoses of skin
cancers made by study patients’ local doctors at other times
wereobtainedandconﬁrmedwithreviewofmedicalrecords.
The use of the SPF 16 sunscreen to the head, neck, arms,
a n dh a n d sh a dn oe ﬀect on the incidence of BCC tumors
or the total number of BCC tumors occurring at these sites.
The incidence of squamous cell carcinoma was signiﬁcantly
reduced in the daily sunscreen group [11]. To assess latency
of the protective eﬀects of sunscreen, an 8-year follow-up
study of all patients included in the original study was
performed by Green and colleagues. Again, a trend, but not
a signiﬁcant reduction in the total number or incidence of
BCC, was observed with daily sunscreen use. When isolated
tothelatefollow-upperiodalone,therewasanon-signiﬁcant
reduction in BCC incidence with daily sunscreen users (RR
0.75, 95% CI 0.49–1.14), indicating a possible trend towards
decreased BCC incidence over longer time periods [12].
3. Discussion:Real-World SunscreenPractices
Green et al.’s data did not support what years of prior
epidemiological and direct evidence would have predicted: a
protective beneﬁt against BCC by using sunscreen. However,
there are four important real-world concepts that were not
addressed by this study: sunscreen abuse, sunscreen misuse,
sunscreen formulation, and cumulative UV exposure.
The idea of sunscreen abuse has been elucidated by three
randomized trials in Europe that examined the behavior of
subjectsonvacationusingsunscreenwithknownSPFvalues.
These studies elucidated the idea of intentional sun exposure
(ISE) and nonintentional sun exposure (NISE). ISE is sun
exposure with an intention to stay in the sun with large
areas of uncovered skin or to acquire a tan [13]. These three
trials found that the subjects with ISE had diﬀering patterns
of behavior with diﬀerent SPF sunscreens assigned for use.
Higher known SPF values were associated with a dramatic
increaseintimespentinthesun,speciﬁcallysunbathing[14–
16]. Higher SPF values were also associated with dramatic
decreases in the amount of sunscreen used, the amount of
clothing used to cover up while in the sun, and the time
of day when sun exposure was obtained, with the high SPF
group sunbathing closer to the noon hours. The abuse of
sunscreen occurs because sunburn is delayed, and the users
are able to practice sun exposure behavior that would not be
possible if they were burning. The users’ perceived endpoint,
sunburn, is thus delayed but still obtained [13].
In Green’s trial, the daily sunscreen group was aware that
they were using sunscreen, and the nonsunscreen group had
no placebo, and thus they knew that they were not being
protected. According to the three aforementioned studies,
this knowledge alone wouldhave signiﬁcantly altered the sun
exposure behavior practices of the two groups.
Sunscreen misuse is nearly ubiquitous when respect is
given to the fact that 2mg/cm2 is the amount of sunscreen
used when SPF is measured. Studies examining the actual
amount applied by most users have revealed amounts closer
to 0.5mg/cm2, or one quarter of the recommended amount,
which yields an eﬀective SPF of about 1/3 the labeled
SPF [17]. Theoretical calculations suggest that there is an
exponential relationship between SPF and the amount of
sunscreen used, and that exponential growth has been
suggested by studies in human skin [17]. Green’s study did
not mention the actual amounts of sunscreen applied, but
with a SPF 16 sunscreen and the realistic amounts used by
the subjects, the actual SPF obtained was likely exponentially
lower than 16. The other form of blatant sunscreen misuse
in Green’s study was the fact that in the daily sunscreen
group, 75% of patients were applying sunscreen to parts of
their body 3-4 days per week, and this was supported by
measured sunscreen weights [12]. In the “daily” group, 75%
ofthesubjectswereusingsunscreenroughly50%ofthetime,
and one may consider that more consistent use of the daily
assignment may have yielded diﬀerent results. In addition,
thecontrolgroupwasallowedtowearsunscreen,and26%of
that no-sunscreen group was in fact wearing sunscreen more
than 2 times per week. Thus, the actual protective beneﬁt is
likely far greater than that stated in Green’s study.
In the 1990s, suspicion of UVA’s role in cutaneous
carcinogenesis fueled an explosion of new “broad spectrum”
sunscreens[13].Onemaybehardpressedtoﬁndasunscreen
resembling the antiquated formulation used in Green’s study
on a shelf for sale today. Green’s study formulation did
utilize avobenzone but had no concurrent UVA stabilizer
[11]. With today’s standards, both the low SPF and lack of
stable UVA coverage provided by this sunscreen may cause
providers and consumers alike to shy away. With the new
USFoodandDrugAdministration(FDA)labelingstandards,
this sunscreen from Green’s study would have to live up
to its purported SPF exactly to claim that it prevents skin
cancer; if it is tested under SPF 15, it could only claim to
prevent sunburn [18]. With issues over the stability of its
UVA coverage, it may not meet the standards that today’s
sunscreen formulations are required to reach to be labeled
broad spectrum [18, 19]. Unfortunately, no randomized
trials exist to date examining what eﬀect a newer sunscreen
formulation may have with relation to basal cell carcinoma
and other skin cancer development.
The likelihood of developing BCC increases with age,
having a median age at diagnosis of 67 years and a mean
age of 64.4 years [20]. The most common age group aﬀected
is 50–80-year-old individuals, with sun damage starting to
accumulate at an early age and likely not manifesting asJournal of Skin Cancer 3
BCC for upwards of 20 years, thus there is a very signiﬁcant
lag time between sun exposure and development of BCC
[20]. With such an apparent contribution of cumulative
UV exposure, it brings to question how applicable a 4.5-
year and even an 8-year extended follow-up period is with
respect to actual BCC risk, when patients have likely been
accruing UV-induced damage for triple that amount of time.
A nonsigniﬁcant downward trend was noted in BCC when
isolated in the extended 8-year endpoint of Green’s study
[12], and a longer period of sunscreen use followed over a
more substantial time frame may very well have shown a
statistically signiﬁcant beneﬁt.
4. Conclusion: Real-World Applications
UV damage causes BCC, and sunscreens block UV. Der-
matologists recommend to their patients the daily use
of high SPF and broad spectrum sunscreens applied in
liberal amounts as part of a photoprotection plan, but no
studies have examined the eﬀects of sunscreen on BCC
with parameters comparable to these recommendations.
Published literature ﬁnding no eﬀect of sunscreen on BCC
did not utilize true daily use of high SPF and broad spectrum
sunscreens with consistent application and likely involved
inadequate amounts applied.
The FDA has addressed some of these issues in its new
rules for sunscreens. By the summer of 2012, sunscreens will
have to provide a minimum SPF of 15 and pass the new
broad spectrum test procedure to claim to protect against
cancer when used with other methods of photoprotection;
if they only achieve one of these two standards, they can only
claim to prevent sunburn [18]. Sunscreens will also not be
able to claim to provide more than two hours of protection
or provide protection immediately after application unless
they submit data to prove these claims and are approved by
the FDA [18]. All sunscreens will require directions on when
to reapply, and sunscreens that are not water resistant will
have to instruct consumers to seek water resistant options if
swimming or sweating [18].
When viewed as a whole, the FDA’s new rules have
addressed many of the real-world concepts that have been
problematic with sunscreen use in the past. Sunscreen abuse,
sunscreen misuse, and cumulative UV exposure have been
addressed with mandatory and deliberate directions on
the label about reapplying, not providing more than two
hours of protection, and sunscreen only being part of a
photoprotection plan. The improved capabilities of sun-
screen formulations have been respected by requiring both
a mandatory SPF minimum and a tested UVA minimum to
claim broad spectrum coverage and prevent skin cancer.
While the conclusions of the studies performed to
date cannot be extrapolated to real-world physician-patient
practicesthathaveproperpatienteducationandcompliance,
the frontier for research with new sunscreen formulations
under new standards and practices is exciting. The ﬁeld of
dermatology can be hopeful that the true role of sunscreen
in the prevention of UV-induced skin cancer may soon be
reliably understood.
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